Company profile: Kedrion Biopharma
1.1 - Company Overview
Company description
- Provider of plasma-derived medicinal products—clotting factors, albumin, and immunoglobulins—for treating hemophilia and immune deficiencies. Offers contract fractionation/manufacturing, technology transfer to build local plasma collection and fractionation, BioSC virus/prion safety studies (PCR, contaminants in cell cultures, in vitro, protein characterization), and pharmacovigilance.
Products and services
- Plasma-derived Medicinal Products: Kedrion produces clotting factors, albumin, and immunoglobulin to treat hemophilia and immune deficiency disorders, using fractionation-based processes to deliver therapeutic plasma proteins
- Contract Manufacturing: Kedrion supplies fractionation and manufacturing services to countries and regions collecting plasma locally yet lacking capacity to process it into medicinal products, via plasma fractionation-focused operations
- Technology Transfer: Kedrion delivers expertise and technology transfer to establish local plasma collection and fractionation facilities, aiming for national self-sufficiency in plasma-derived products through facility-based capability building
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Kedrion Biopharma
PhosImmune
HQ: United States
Website
- Description: Provider of clinical-stage therapeutic cancer vaccines enabled by a library of unique, aberrantly phosphorylated tumor antigens (PTAs) directly implicated in metastasis, addressing the need for high-quality tumor antigens for use in new and more effective cancer vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PhosImmune company profile →
Eureka Therapeutics
HQ: United States
Website
- Description: Provider of T-cell therapies via the ARTEMIS Cell Receptor Platform to engineer T cells to target and destroy cancer cells; the E-ALPHA Phage Display Platform to generate specific antibodies against cancer targets, including TCR-mimic antibodies for solid tumors; and an Expanded Access Policy offering investigational cell therapy under certain conditions to patients with serious or life-threatening diseases who have no other treatment options.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eureka Therapeutics company profile →
Cangene
HQ: United States
Website
- Description: Provider of immune therapeutics through fully integrated development and manufacturing, with a solid track record of developing and commercializing plasma-derived products that address multiple therapeutic areas; first drug WinRho SDF has been commercially available since 1980.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cangene company profile →
Hookipa Pharma
HQ: United States
Website
- Description: Provider of arenavirus-based immunotherapies for infectious diseases and cancer, using proprietary TheraT and Vaxwave vector platforms to elicit neutralizing antibodies and T cell responses. Offerings include HB-200 for HPV-associated head and neck cancers, HB-700 for KRAS-mutated cancers, and replicating and non-replicating technologies for oncology and prophylactic immunization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hookipa Pharma company profile →
NextCure
HQ: United States
Website
- Description: Provider of biopharmaceutical discovery and development focused on next-generation immuno-oncology-based drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NextCure company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Kedrion Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Kedrion Biopharma
2.2 - Growth funds investing in similar companies to Kedrion Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Kedrion Biopharma
4.2 - Public trading comparable groups for Kedrion Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →